← Back to Search

Severe COVID-19 ZYESAMI™ for COVID-19 (AVICOVID-2 Trial)

Phase 2 & 3
Waitlist Available
Research Sponsored by NeuroRx, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

Summary

This trial is studying if a synthetic version of a hormone called Vasoactive Intestinal Polypeptide (VIP) can help improve symptoms and prevent progression to severe COVID-19 in people who have not yet developed respiratory failure.

Eligible Conditions
  • COVID-19
  • Coronavirus Disease
  • Acute Respiratory Distress Syndrome
  • Acute Lung Injury
  • Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
  • Shortness of Breath

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression to Respiratory Failure
Secondary study objectives
Blood oxygenation
Distance walked in six minutes
RPD Dyspnea Scale

Trial Design

2Treatment groups
Experimental Treatment
Group I: Severe COVID-19 ZYESAMI™Experimental Treatment2 Interventions
Patients with Severe COVID-19 to be treated with inhaled ZYESAMI™ (aviptadil) by mesh nebulizer 100μg 3x daily
Group II: Severe COVID-19 PlaceboExperimental Treatment2 Interventions
Patients with Severe COVID-19 to be treated with inhaled placebo 3x daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

NeuroRx, Inc.Lead Sponsor
12 Previous Clinical Trials
1,015 Total Patients Enrolled
4 Trials studying COVID-19
676 Patients Enrolled for COVID-19
APR Applied Pharma Research s.a.Lead Sponsor
13 Previous Clinical Trials
1,308 Total Patients Enrolled
3 Trials studying COVID-19
260 Patients Enrolled for COVID-19
Jonathan C Javitt, MD, MPHStudy ChairNeuroRx
6 Previous Clinical Trials
277 Total Patients Enrolled
3 Trials studying COVID-19
203 Patients Enrolled for COVID-19
~31 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top